Posts Tagged ‘ Cyclacel Pharmaceuticals ’

Investment Opportunities with Five Frontline Therapies for AML

0
September 6, 2010
Investment Opportunities with Five Frontline Therapies for AML

Acute myelogenous leukemia is a fast-growing cancer of the blood and bone marrow.  Unformed cells called myeloblasts, or “blasts,” reside in the bone marrow and normally become a particular kind of cell – a white blood cell, red blood cell, or platelet.  In AML, abnormal blasts produce white blood cells that do not...
Read More »

Biotech Deal Activity Declines…The Pause that Refreshes?

1
January 14, 2010
Biotech Deal Activity Declines…The Pause that Refreshes?

* MD Becker Partners reporting live from the JP Morgan Healthcare Conference This week, nearly 6,500 registrants gathered in San Francisco, California for the JP Morgan Healthcare Conference to hear 25-minute presentations from 338 life science companies.  For industry executives and investors, the annual event serves as a good barometer for the rest of...
Read More »

Buyout Buzz at ASH Hematology Confab

1
December 7, 2009
Buyout Buzz at ASH Hematology Confab

Scientific and medical advances weren’t the only topic of discussion at the 51st American Society of Hematology Annual Meeting that began over the weekend in New Orleans, LA, as merger and acquisition activity took center stage. Early this morning, Celgene Corporation (CELG) announced the acquisition of privately-held Gloucester Pharmaceuticals for $340 million in...
Read More »

Biotech Baker’s Dozen to Watch at Hematology Meeting

2
November 29, 2009
Biotech Baker’s Dozen to Watch at Hematology Meeting

The 51st American Society of Hematology Annual Meeting will take place December 5-8, 2009, at the Ernest N. Morial Convention Center in New Orleans, LA.  This is the premier event for the hematology industry, attracting more than 20,000 hematologists and other health-care professionals. In this regard, Celgene Corporation (CELG) recently announced that data...
Read More »